Harmony Biosciences Holdings, Inc. $HRMY Shares Acquired by American Century Companies Inc.

American Century Companies Inc. lifted its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 11.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,669,565 shares of the company’s stock after purchasing an additional 168,145 shares during the quarter. American Century Companies Inc. owned about 2.90% of Harmony Biosciences worth $46,013,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Parkside Financial Bank & Trust increased its holdings in Harmony Biosciences by 4,185.2% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,157 shares of the company’s stock worth $37,000 after buying an additional 1,130 shares during the period. Tower Research Capital LLC TRC lifted its stake in Harmony Biosciences by 338.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,511 shares of the company’s stock valued at $111,000 after acquiring an additional 2,711 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new stake in shares of Harmony Biosciences in the 2nd quarter valued at $120,000. Ameritas Investment Partners Inc. increased its stake in shares of Harmony Biosciences by 12.0% in the second quarter. Ameritas Investment Partners Inc. now owns 4,466 shares of the company’s stock worth $141,000 after acquiring an additional 479 shares during the period. Finally, EMC Capital Management acquired a new stake in shares of Harmony Biosciences in the second quarter worth $195,000. Institutional investors and hedge funds own 86.23% of the company’s stock.

Harmony Biosciences Trading Down 0.1%

Shares of NASDAQ:HRMY opened at $28.51 on Friday. The business’s 50 day moving average price is $35.21 and its 200-day moving average price is $33.86. Harmony Biosciences Holdings, Inc. has a 1 year low of $25.52 and a 1 year high of $40.87. The firm has a market capitalization of $1.65 billion, a price-to-earnings ratio of 10.52, a price-to-earnings-growth ratio of 0.39 and a beta of 0.88. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.60 and a quick ratio of 3.58.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Tuesday, February 24th. The company reported $0.38 EPS for the quarter, missing the consensus estimate of $0.84 by ($0.46). The company had revenue of $243.78 million during the quarter, compared to analysts’ expectations of $240.04 million. Harmony Biosciences had a return on equity of 19.86% and a net margin of 18.29%.Harmony Biosciences’s revenue was up 21.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.85 EPS. On average, equities research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Mizuho set a $50.00 target price on shares of Harmony Biosciences in a research report on Thursday, February 19th. Wall Street Zen lowered Harmony Biosciences from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Truist Financial cut Harmony Biosciences from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. Deutsche Bank Aktiengesellschaft downgraded Harmony Biosciences from a “buy” rating to a “hold” rating and set a $31.00 target price on the stock. in a research note on Monday, February 23rd. Finally, UBS Group reduced their price target on Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $42.67.

Insider Transactions at Harmony Biosciences

In related news, CFO Sandip Kapadia sold 3,746 shares of Harmony Biosciences stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $37.15, for a total value of $139,163.90. Following the sale, the chief financial officer directly owned 24,521 shares in the company, valued at approximately $910,955.15. The trade was a 13.25% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Jeffrey M. Dayno sold 25,933 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $40.11, for a total value of $1,040,172.63. The SEC filing for this sale provides additional information. Insiders have sold 50,640 shares of company stock valued at $1,932,256 in the last three months. Corporate insiders own 23.60% of the company’s stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.